The DOI matches its Crossref record.
Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers
Abstract
At the time of diagnosis, many sarcoidosis patients have no clinical indication for corticosteroid therapy, and prognostic parameters predicting deterioration are missing. In the present study, we investigated parameters derived from bronchoalveolar lavage (BAL) and serum in 77 patients with recently diagnosed sarcoidosis to test their predictive value. Patients were divided into a group with (Group A, n = 37) and a group without (Group B, n = 40) indications for therapy, and the course of the disease was evaluated after 5.7 +/- 0.4 mo. The CD4+/CD8+ lymphocyte ratio and percentage of BAL lymphocytes were of no predictive value. Release of tumor necrosis factor-alpha (TNF-alpha) from cultured alveolar macrophages (AM) was significantly increased in both groups (Group A = 1,872 +/- 428 pg/ml; Group B = 1,561 +/- 449 pg/ml) as compared with controls (220 +/- 37 pg/ml). In Group B, however, patients with a high level of TNF-alpha release had a significantly greater risk of disease progression than did those with normal TNF-alpha release (43.8% versus 8.3%, respectively). From the serologic parameters investigated, consisting of neopterin, angiotensin converting enzyme (ACE), and soluble interleukin-2 receptor (sIL-2R), only the last was of significant predictive value; 42.1% of sarcoidosis patients in Group B with a high level of sIL-2R experienced disease progression, whereas none of those with a normal level did. We conclude that TNF-alpha release and sIL-2R are suitable parameters for predicting disease progression in sarcoid patients who have no indication for therapy at the time of disease diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.ats4-99 · Cited by 1,902
Spagnolo, P., Rossi, G., Trisolini, R., Sverzellati, N., Baughman, R. P., & Wells, A. U. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30064-x · Cited by 949
Baughman, R. P., Lower, E. E., & du Bois, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12888-7 · Cited by 657
Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis
Utz, J. P., Limper, A. H., Kalra, S., Specks, U., Scott, J. P., Vuk-Pavlovic, Z., & Schroeder, D. R. (2003) · Chest · doi:10.1378/chest.124.1.177 · Cited by 390
Pechkovsky, D. V., Prasse, A., Kollert, F., Engel, K. M. Y., Dentler, J., Luttmann, W., Friedrich, K., Müller-Quernheim, J., & Zissel, G. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.017 · Cited by 328
Self-citation
Metadata
- Authors
- ZIEGENHAGEN, M. W., BENNER, U. K., ZISSEL, G., ZABEL, P., SCHLAAK, M., & MÜLLER-QUERNHEIM, J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-11-01
- Volume
- 156
- Issue
- 5
- Pages
- 1586-1592
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1967956104
- Cited by
- 237
- References
- 0
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. https://app.cochat.ai/papers/10.1164/ajrccm.156.5.97-02050
- The paper
- ZIEGENHAGEN, M. W., BENNER, U. K., ZISSEL, G., ZABEL, P., SCHLAAK, M., & MÜLLER-QUERNHEIM, J. (1997). Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.156.5.97-02050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.